glp 1 agonist pharmacology Frontiers Frontiers | Mechanisms of action

The study confirmed that lixisenatide exerts a more pronounced effect on postprandial glycemic variations with a modest effect on fasting glucose levels

Plasma contains the soluble form of DPP-4

Beyond preclinical evidence, clinical data underscore the therapeutic relevance of GLP-1RAs

The primary pharmacodynamic distinctions between long-acting and short-acting GLP-1RAs are that long-acting agonists augment insulin production and suppress glucagon generation to lower postprandial glucose and fasting plasma glucose, while short-acting agonists chiefly lower postprandial glucose by delaying gastric emptying

Diabetes (2018) 67

Haufe S, Kaminski J, Utz W, Haas V, Mhler A, Daniels MA, et al